GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Argent Biopharma Ltd (ASX:RGT) » Definitions » ROC (Joel Greenblatt) %

Argent Biopharma (ASX:RGT) ROC (Joel Greenblatt) % : -627.41% (As of Dec. 2024)


View and export this data going back to 2006. Start your Free Trial

What is Argent Biopharma ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Argent Biopharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was -627.41%.

The historical rank and industry rank for Argent Biopharma's ROC (Joel Greenblatt) % or its related term are showing as below:

ASX:RGT' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1154.8   Med: -241.63   Max: -120.25
Current: -470.5

During the past 13 years, Argent Biopharma's highest ROC (Joel Greenblatt) % was -120.25%. The lowest was -1154.80%. And the median was -241.63%.

ASX:RGT's ROC (Joel Greenblatt) % is ranked worse than
92.9% of 1014 companies
in the Drug Manufacturers industry
Industry Median: 9.475 vs ASX:RGT: -470.50

Argent Biopharma's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.80% per year.


Argent Biopharma ROC (Joel Greenblatt) % Historical Data

The historical data trend for Argent Biopharma's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Argent Biopharma ROC (Joel Greenblatt) % Chart

Argent Biopharma Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -679.98 -235.79 -201.26 -242.44 -240.82

Argent Biopharma Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -231.73 -235.63 -187.87 -312.15 -627.41

Competitive Comparison of Argent Biopharma's ROC (Joel Greenblatt) %

For the Drug Manufacturers - Specialty & Generic subindustry, Argent Biopharma's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Argent Biopharma's ROC (Joel Greenblatt) % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Argent Biopharma's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Argent Biopharma's ROC (Joel Greenblatt) % falls into.


;
;

Argent Biopharma ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.14 + 0.875 + 0.685) - (2.719 + 0.554 + 8.679)
=-10.252

Working Capital(Q: Dec. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.343 + 0.329 + 0.655) - (4.571 + 0 + -0.00099999999999945)
=-3.243

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Argent Biopharma for the quarter that ended in Dec. 2024 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2024  Q: Dec. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-24.262/( ( (6.72 + max(-10.252, 0)) + (1.014 + max(-3.243, 0)) )/ 2 )
=-24.262/( ( 6.72 + 1.014 )/ 2 )
=-24.262/3.867
=-627.41 %

Note: The EBIT data used here is two times the semi-annual (Dec. 2024) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Argent Biopharma  (ASX:RGT) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Argent Biopharma ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Argent Biopharma's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Argent Biopharma Business Description

Traded in Other Exchanges
Address
295 Rokeby Road, Suite 1, Subiaco, WA, AUS, 6008
Argent Biopharma Ltd is a drug discovery company that addresses unmet medical needs. The company focuses on multidisciplinary methods with nanotechnology, developing multi-target therapies for comprehensive disease management, especially in the central nervous system and immunology treatments. The products of the company include CannEpil for refractory epilepsy and cerebral palsy, CimetrA for acute lung injury, and ARDS, and CogniCann for enhancing the quality of life in dementia and Alzheimer's patients, with additional treatments in development, and others.

Argent Biopharma Headlines

From GuruFocus

Royce Global Value Trust (NYSE: RGT) as of Feb 28, 2023

By PRNewswire PRNewswire 03-28-2023

Royce Global Value Trust (NYSE: RGT) as of Dec 31, 2022

By PRNewswire PRNewswire 01-25-2023

Royce Global Value Trust (NYSE: RGT) as of Apr 30, 2023

By PRNewswire PRNewswire 05-25-2023

Royce Global Value Trust (NYSE: RGT) as of Nov 30, 2022

By PRNewswire PRNewswire 12-29-2022